These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18766492)

  • 1. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy--a case report.
    Sayed-Noor AS; Sjödén GO
    Acta Orthop; 2008 Aug; 79(4):565-7. PubMed ID: 18766492
    [No Abstract]   [Full Text] [Related]  

  • 2. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?
    Kwek EB; Goh SK; Koh JS; Png MA; Howe TS
    Injury; 2008 Feb; 39(2):224-31. PubMed ID: 18222447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features.
    Chan SS; Rosenberg ZS; Chan K; Capeci C
    AJR Am J Roentgenol; 2010 Jun; 194(6):1581-6. PubMed ID: 20489100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Atypical subtrochanteric femur fracture under alendronate therapy in spite of an intramedullar implant].
    Sobotta HP; Gösling T
    Unfallchirurg; 2017 Feb; 120(2):171-175. PubMed ID: 27812727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical fractures on long term bisphosphonates therapy.
    Hussein W; Cunningham C; Logan H; Fallon C; Murphy S
    Ir Med J; 2011; 104(10):308, 310. PubMed ID: 22256444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate-induced atypical subtrochanteric femoral fracture.
    Vaishya R; Vaish A; Nadeem A
    BMJ Case Rep; 2013 Nov; 2013():. PubMed ID: 24287483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
    Sánchez A; Blanco R
    Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signs of Insufficiency Fractures Overlooked in a Patient Receiving Chronic Bisphosphonate Therapy.
    Shaikh W; Morris D; Morris S
    J Am Board Fam Med; 2016; 29(3):404-7. PubMed ID: 27170798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
    Angthong C; Angthong W
    J Med Assoc Thai; 2011 Dec; 94 Suppl 7():S214-20. PubMed ID: 22619933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
    Goh SK; Yang KY; Koh JS; Wong MK; Chua SY; Chua DT; Howe TS
    J Bone Joint Surg Br; 2007 Mar; 89(3):349-53. PubMed ID: 17356148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy.
    Kajino Y; Kabata T; Watanabe K; Tsuchiya H
    J Orthop Sci; 2012 May; 17(3):313-8. PubMed ID: 21604044
    [No Abstract]   [Full Text] [Related]  

  • 12. [Subtrochanteric pathological fracture on bisphosphonates].
    Mathonet PY; Willems S; Ciornohac JF
    Rev Med Liege; 2018 Feb; 73(2):56-60. PubMed ID: 29517866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral atypical femoral fractures after long-term alendronate therapy: a case report.
    Bamrungsong T; Pongchaiyakul C
    J Med Assoc Thai; 2010 May; 93(5):620-4. PubMed ID: 20524451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
    Bize R; Lamy O; Peytremann-Bridevaux I
    Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
    [No Abstract]   [Full Text] [Related]  

  • 15. Bisphosphonate-related subtrochanteric femoral fractures.
    Gunawardena I; Baxter M; Rasekh Y
    Am J Geriatr Pharmacother; 2011 Jun; 9(3):194-8. PubMed ID: 21470918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case reports: two femoral insufficiency fractures after long-term alendronate therapy.
    Sayed-Noor AS; Sjödén GO
    Clin Orthop Relat Res; 2009 Jul; 467(7):1921-6. PubMed ID: 19198962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment with bisphosphonates as a possible cause of bilateral spontaneous atypical femoral fracture].
    Rasmussen M; Lange J
    Ugeskr Laeger; 2012 Jan; 174(1-2):32-3. PubMed ID: 22233718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rational approach to management of alendronate-related subtrochanteric fractures.
    Das De S; Setiobudi T; Shen L; Das De S
    J Bone Joint Surg Br; 2010 May; 92(5):679-86. PubMed ID: 20436006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Femoral shaft fractures in the elderly--role of prior bisphosphonate therapy.
    Ng YH; Gino PD; Lingaraj K; Das De S
    Injury; 2011 Jul; 42(7):702-6. PubMed ID: 21316051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture.
    Cross MB; Nam D; van der Meulen MC; Bostrom MP
    J Bone Joint Surg Br; 2012 Jul; 94(7):994-7. PubMed ID: 22733959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.